Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction and Premature Ovarian Insufficiency
-
- STATUS
- Recruiting
-
- End date
- Jul 31, 2030
-
- participants needed
- 100
-
- sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Summary
- Background
Turner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to become pregnant and have their own child. Researchers want to learn more about why this happens and if freezing ovarian tissue allows for fertility preservation.
- Objective
To find out why females with certain conditions have can have premature ovarian insufficiency (POI or early menopause) and trouble getting pregnant and if freezing the tissue from their ovary will help them have their own child in the future.
- Eligibility
Females aged 4-12 who have Turner Syndrome or galactosemia. Also, females aged 13 21 with premature ovarian insufficiency.
- Design
Participants will be screened with a medical history.
Participants may have a physical exam and blood tests. Their body measurements may be taken. These include weight, height, arm span, skin fold, and sitting height. They may fill out surveys about their quality of life, body image, and health.
Participants may have a transabdominal pelvic ultrasound. A probe will be placed on their belly and will take pictures of the organs in the pelvis. They may have a transvaginal pelvic ultrasound performed while asleep in the operating room if needed.
Participants will have surgery to remove an ovary. The removed tissue will be frozen and stored. The tissue will have to be stored for many years. NIH will pay to store the tissue for 1 year. After that, participants will have to pay for storage.
A piece of the ovary (no more than 20%) will be used for research
Travel, lodging and meals for participants traveling greater than 50 miles will be reimbursed based off the government rate. Local participants will not be reimbursed.
Participants will have a checkup 6 weeks after surgery one or more follow-up visits 6 18 months after surgery. They may have phone follow-up every 12 24 months after surgery.
Participation will last 30 years.
Description
Study Description:
Ovarian tissue cryopreservation and evaluation in individuals with Turner Syndrome, individual with Turner syndrome with Y material who undergo prophylactic gonadectomy, galactosemia, post- menarcheal adolescents with recent premature ovarian insufficiency, and adolescents with diminished ovarian reserve (DOR) who have contraindication to ovarian stimulation as well as those with diminished ovarian reserve who did not respond to ovarian stimulation, which are associated with acute or chronic effects on ovarian function and reproduction.
- Objectives
Primary Objectives: After initial evaluation of number and quality of follicles before and after cryopreservation and thawing, the remaining tissue will be utilized to perform research regarding mechanisms of follicle loss in Turner and galactosemia as well as post-menarcheal adolescent individuals with a recent diagnosis of POI
- We will perform single cell/nucleus RNA sequencing on the tissue collected from study participants and ovaries from cadaveric organ donors on cardiopulmonary support.
- We will perform single cell/nucleus RNA sequencing on fresh ovarian tissue and compare it to frozen and thawed tissue
Hypothesis: Single cell/nucleus RNA sequencing from tissue obtained from ovaries in individuals with these conditions will differ significantly from that of controls. Such differences may allow for further hypothesis development regarding the underlying mechanism of follicle loss and/or dysfunction in individuals with these conditions.
Secondary Objective: This protocol is designed to evaluate the feasibility (meaning a reasonable expectation of future fertility based on the anatomy, histology, and physiology of fresh ovarian tissue as well as the effects after freezing and thawing) of ovarian tissue cryopreservation (OTC) for fertility preservation in children with increased risk of loss of ovarian function due to Turner syndrome (with or without Y material) or galactosemia and post-menarcheal adolescents with a recent development of premature ovarian insufficiency (POI) or with diminished ovarian reserve (those who do not respond to ovarian stimulation for oocyte cryopreservation due to lower follicle counts).
- The feasibility will be evaluated through evaluation of number and quality of follicles found in the tissue prior to freezing and after thawing.
- Lack of follicles in the ovarian tissue will confirm that OTC is not a viable option for this
population.
3. An attempt to correlate laboratory and imaging markers with follicle presence and number will be made.
Hypothesis: Young individuals with Turner syndrome and galactosemia and adolescents with recent POI, harbor populations of follicles which may be preserved through ovarian tissue cryopreservation for future fertility.
- There will be a variety of follicular findings which will correlate with patient s anti-Mullerian hormone (AMH), age and underlying condition.
- Loss of follicles with cryopreservation and thawing will be similar to that of non-affected
individuals.
Tertiary Objectives: Research regarding inhibition and activation of follicles within the tissue
will be undertaken.
- Tissue will be treated with known inhibitors and activators and single cell/nucleus RNA
sequencing will be performed in order to assess gene expression before and after treatment
Hypothesis: Primordial follicles within ovarian tissue in individuals with these conditions
may be inhibited from activating. Such techniques may allow for a decrease in follicle
loss with freezing and thawing as well as possible future development of novel treatments to
prevent accelerated follicle loss in individuals and adolescent affected by these conditions.
Promoting follicle activation prior to re- implantation of the tissue may improve the possibility of achieving pregnancy after tissue re-implantation
- Endpoints
Primary Endpoints:
- Tissue for research: Single cell/nucleus RNA sequencing will be performed on tissues of
affected individuals and compared to age matched controls who will be cadaveric organ donors on cardiopulmonary support. This will allow for specific cellular type comparisons within the ovary and exploratory research regarding possible mechanisms of follicle loss in these populations.
2. Single cell/nucleus RNA sequencing on fresh compared to frozen and thawed tissue. This
will assess what transcription changed occur due to the freezing process.
Secondary Endpoint:
- Evaluation of density and quality of follicles in the ovaries of individuals with Turner syndrome (with or without Y material), galactosemia and post-menarcheal adolescent with premature ovarian insufficiency or with diminished ovarian reserve (those who do not respond to ovarian stimulation for oocyte cryopreservation due to lower follicle counts)
- Correlation of follicle density and quality with markers such as age, AMH, condition.
- Comparison of hormone levels such as AMH, FSH, LH, and Estradiol between patients and controls.
Tertiary Endpoint
-Evaluate changes in single cell/nucleus RNA sequencing in tissue before and after treatment with primordial follicle inhibitors and activators. The remaining tissue will be cryopreserved for future experiments.
Details
| Condition | Ovarian Disfunction, Post-menarcheal Adolescents, Turner Syndrome, Galactosemia |
|---|---|
| Clinical Study Identifier | NCT04948658 |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Last Modified on | 4 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer